Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells

Cancer Immunology, Immunotherapy

Volumn 60, Issue 6, 2011, Pages 857-867

  Anderson, Karen S ^a   Zeng, Wanyong ^a   Sasada, Tetsuro ^a   Choi, Jaewon ^a   Riemer, Angelika B ^a   Su, Mei ^a   Drakoulakos, Donna ^a   Kang, Yoon Joong ^a   Brusic, Vladimir ^a   Wu, Catherine ^a   Reinherz, Ellis L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen processing; Dendritic cells; Tumor immunity; Vaccination

Indexed keywords

CD40 ANTIGEN; CYTOCHROME P450 1B1; IMMUNOGLOBULIN; INFLUENZA VIRUS ANTIGEN; MELAN A; PROTEASOME; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; DENDRITIC CELL; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HLA-A ANTIGENS; HUMANS; K562 CELLS; LYMPHOCYTE ACTIVATION; MALE; TRANSFECTION;

EID: 79959754730     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0995-5     Document Type: Article

References (40)

1. BJ Van den Eynde S Morel 2001 Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome Curr Opin Immunol 13 2 147 153 (Pubitemid 32176032)
2. J Dannull DT Lesher R Holzknecht W Qi G Hanna H Seigler, et al. 2007 Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity Blood 110 13 4341 4350 (Pubitemid 351377799)
3. N Meidenbauer A Zippelius MJ Pittet M Laumer S Vogl J Heymann, et al. 2004 High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma Cancer Res 64 17 6319 6326 (Pubitemid 39129437)
4. S Heink B Fricke D Ludwig PM Kloetzel E Kruger 2006 Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency Cancer Res 66 2 649 652 (Pubitemid 43165925)
5. MS von Bergwelt-Baildon RH Vonderheide B Maecker N Hirano KS Anderson MO Butler, et al. 2002 Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application Blood 99 9 3319 3325 (Pubitemid 34525313)
6. JL Schultze S Grabbe MS von Bergwelt-Baildon 2004 DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy Trends Immunol 25 12 659 664 (Pubitemid 39457979)
7. E Kondo MS Topp HP Kiem Y Obata Y Morishima K Kuzushima, et al. 2002 Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells J Immunol 169 4 2164 2171 (Pubitemid 34857684)
8. CM Coughlin BA Vance SA Grupp RH Vonderheide 2004 RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy Blood 103 6 2046 2054 (Pubitemid 38326219)
9. R Lapointe A Bellemare-Pelletier F Housseau J Thibodeau P Hwu 2003 CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells Cancer Res 63 11 2836 2843 (Pubitemid 36667155)
10. M von Bergwelt-Baildon B Maecker J Schultze JG Gribben 2004 CD40 activation: potential for specific immunotherapy in B-CLL Ann Oncol 15 6 853 857 (Pubitemid 39004338)
11. von Bergwelt-Baildon M. Schultze J.L. Maecker B. Menezes I. Nadler L.M. Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63:2836-2843. Cancer Res 2004 64(11):4055-4056; Author reply 6-7
12. MM Suhoski TN Golovina NA Aqui VC Tai A Varela-Rohena MC Milone, et al. 2007 Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules Mol Ther 15 5 981 988 (Pubitemid 46621657)
13. MO Butler JS Lee S Ansen D Neuberg FS Hodi AP Murray, et al. 2007 Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell Clin Cancer Res 13 6 1857 1867 (Pubitemid 46952956)
14. N Hirano MO Butler Z Xia S Ansen MS von Bergwelt-Baildon D Neuberg, et al. 2006 Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity Blood 107 4 1528 1536 (Pubitemid 43242391)
15. N Hirano MO Butler Z Xia A Berezovskaya AP Murray S Ansen, et al. 2006 Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses Clin Cancer Res 12 10 2967 2975 (Pubitemid 43837340)
16. B Maecker DH Sherr RH Vonderheide MS von Bergwelt-Baildon N Hirano KS Anderson, et al. 2003 The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells Blood 102 9 3287 3294 (Pubitemid 37314768)
17. JG Gribben DP Ryan R Boyajian RG Urban ML Hedley K Beach, et al. 2005 Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy Clin Cancer Res 11 12 4430 4436 (Pubitemid 40825633)
18. U Gileadi HT Moins-Teisserenc I Correa BL Booth Jr PR Dunbar AK Sewell, et al. 1999 Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein J Immunol 163 11 6045 6052
19. XF Yang CJ Wu S McLaughlin A Chillemi KS Wang C Canning, et al. 2001 CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia Proc Natl Acad Sci USA 98 13 7492 7497 (Pubitemid 32567976)
20. K Blomberg C Granberg I Hemmila T Lovgren 1986 Europium-labelled target cells in an assay of natural killer cell activity. II. A novel non-radioactive method based on time-resolved fluorescence. significance and specificity of the method J Immunol Methods 92 1 117 123 (Pubitemid 16051388)
21. JD Altman PA Moss PJ Goulder DH Barouch MG McHeyzer-Williams JI Bell, et al. 1996 Phenotypic analysis of antigen-specific T lymphocytes Science 274 5284 94 96 (Pubitemid 26332731)
22. M Nielsen C Lundegaard O Lund C Kesmir 2005 The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage Immunogenetics 57 1-2 33 41 (Pubitemid 40591245)
23. MM Schuler MD Nastke S Stevanovikc 2007 SYFPEITHI: database for searching and T-cell epitope prediction Methods Mol Biol 409 75 93
24. Rasband WS. Image J. http://rsbinfonihgov/ij/, 1997-2009
25. S Morel F Levy O Burlet-Schiltz F Brasseur M Probst-Kepper AL Peitrequin, et al. 2000 Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells Immunity 12 1 107 117 (Pubitemid 30069219)
26. AM De Maziere K Muehlethaler E van Donselaar S Salvi J Davoust JC Cerottini, et al. 2002 The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins Traffic 3 9 678 693
27. KS Anderson J Alexander M Wei P Cresswell 1993 Intracellular transport of class I MHC molecules in antigen processing mutant cell lines J Immunol 151 7 3407 3419 (Pubitemid 23282653)
28. DR Peaper PA Wearsch P Cresswell 2005 Tapasin and ERp57 form a stable disulfide-linked dimer within the MHC class I peptide-loading complex EMBO J 24 20 3613 3623 (Pubitemid 41509368)
29. F Ossendorp N Fu M Camps F Granucci SJ Gobin PJ van den Elsen, et al. 2005 Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells J Immunol 174 12 7815 7822 (Pubitemid 40806290)
30. G Niedermann G King S Butz U Birsner R Grimm J Shabanowitz, et al. 1996 The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides Proc Natl Acad Sci USA 93 16 8572 8577 (Pubitemid 26269601)
31. A Craiu T Akopian A Goldberg KL Rock 1997 Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide Proc Natl Acad Sci USA 94 20 10850 10855 (Pubitemid 27430824)
32. RE Toes AK Nussbaum S Degermann M Schirle NP Emmerich M Kraft, et al. 2001 Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products J Exp Med 194 1 1 12 (Pubitemid 32660433)
33. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 9 909 915 (Pubitemid 39273730)
34. J Banchereau AK Palucka 2005 Dendritic cells as therapeutic vaccines against cancer Nat Rev Immunol 5 4 296 306 (Pubitemid 40516155)
35. L Chapatte M Ayyoub S Morel AL Peitrequin N Levy C Servis, et al. 2006 Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses Cancer Res 66 10 5461 5468 (Pubitemid 43844974)
36. J Chapiro S Claverol F Piette W Ma V Stroobant B Guillaume, et al. 2006 Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation J Immunol 176 2 1053 1061 (Pubitemid 43099706)
37. M Basler J Moebius L Elenich M Groettrup JJ Monaco 2006 An altered T cell repertoire in MECL-1-deficient mice J Immunol 176 11 6665 6672 (Pubitemid 43787850)
38. Peters B (2003) Modeling the MHC-I pathway. Humboldt University, Berlin, Germany
39. HH Lin S Ray S Tongchusak EL Reinherz V Brusic 2008 Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research BMC Immunol 9 8
40. RT Maziarz SJ Mentzer SJ Burakoff DV Faller 1990 Distinct effects of interferon-gamma and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killer-mediated lysis Cell Immunol 130 2 329 338 (Pubitemid 20368052)